Antitope and Baylor Institute for Immunology Research to Collaborate on Cell Line for Novel Therapeutic Dendritic-cell-targeting Vaccine

11-Jun-2014 - United Kingdom

Antitope Limited, an Abzena company, announced that it will develop a manufacturing cell line for the Baylor Institute for Immunology Research (“BIIR” using its Composite CHO™ technology. BIIR is developing a range of therapeutic vaccines for the treatment of cancer and other diseases, and Antitope will develop a cell line for the production of BIIR’s novel dendritic-cell-targeting vaccine for the treatment of head and neck and cervical cancer.

Antitope has developed the Composite CHO™ technology for the generation of stable cell lines producing high yields of proteins and antibodies ready for cGMP manufacture. The current project represents another milestone in the relationship between Antitope and BIIR, initiated several years ago when Antitope applied its Composite Human Antibody™ technology to humanize several novel BIIR antibodies. The humanized antibodies have been an important tool for BIIR in the development of its therapeutic vaccines.

Other news from the department science

Most read news

More news from our other portals

Fighting cancer: latest developments and advances